US Patent

US11382923 — Stable liquid formulations of cyclophosphamide and processes to prepare the same

Formulation · Assigned to Dr Reddys Laboratories Ltd · Expires 2035-12-01 · 10y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable liquid formulations of the drug cyclophosphamide, also known as Cytoxan, with a moisture content of less than 2.0% by weight.

USPTO Abstract

The present invention relates to stable liquid pharmaceutical formulations of cyclophosphamide comprising cyclophosphamide and at least one pharmaceutically acceptable excipient wherein moisture content of the liquid formulation is less than about 2.0% by weight. The invention further relates to stable liquid formulations of cyclophosphamide prepared by a process comprising a step of reducing the moisture content from cyclophosphamide or liquid compositions of cyclophosphamide or both. The invention further relate to method of using such stable liquid formulations of cyclophosphamide for parenteral administration either as ready-to-use or ready-to-dilute for treating various cancer disorders.

Drugs covered by this patent

Patent Metadata

Patent number
US11382923
Jurisdiction
US
Classification
Formulation
Expires
2035-12-01
Drug substance claim
No
Drug product claim
Yes
Assignee
Dr Reddys Laboratories Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.